Clinical Trial Update: Frailty Index and Geriatric Assessment in Predicting Toxicity to Front-Line Chemotherapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer

View source ↗

Summary

This clinical trial evaluated whether frailty index and geriatric assessment can predict toxicity from front-line chemotherapy in patients with stage IV non-sma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: Wake Forest University Health Sciences | Conditions: Recurrent Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer | Status: COMPLETED